SCHEMBL587550

SCHEMBL587550

CC(C)(C)OC(=O)N1CCNCC1.CC(C)(C)OC(=O)N1CCNCC1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
MAPK1 P28482 1/20 0.49
HPGD P15428 1/20 0.49
RECQL P46063 1/20 0.46
EPHX1 P07099 1/20 0.46
NR1H2 P55055 1/20 0.46
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45
EPHX2 P34913 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8286 1.00 USP2 (0.58) USP2SMN1; SMN2MAPK1HPGDRECQL
SCHEMBL12005408 1.00 USP2 (0.58) USP2SMN1; SMN2MAPK1HPGDRECQL
SCHEMBL1225127 1.00 USP2 (0.58) USP2SMN1; SMN2MAPK1HPGDRECQL
SCHEMBL2220355 0.98 USP2 (0.56) USP2SMN1; SMN2MAPK1HPGDRECQL
SCHEMBL14653343 0.98 USP2 (0.56) USP2SMN1; SMN2MAPK1HPGDRECQL
Ammonia Solution, Strong SCHEMBL18035416 0.98 USP2 (0.56) USP2SMN1; SMN2MAPK1HPGDRECQL
Hydrochloric Acid SCHEMBL1904026 0.98 USP2 (0.56) USP2SMN1; SMN2MAPK1HPGDRECQL
Hydrochloric Acid SCHEMBL4141237 0.98 USP2 (0.56) USP2SMN1; SMN2MAPK1HPGDRECQL
SCHEMBL132585 0.98 USP2 (0.56) USP2SMN1; SMN2MAPK1HPGDRECQL
SCHEMBL2934532 0.98 USP2 (0.56) USP2SMN1; SMN2MAPK1HPGDRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866430-B2 Naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-09 US disclosed
US-20230089255-A1 COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2023-03-23 US disclosed
CN-112724078-B Method for removing impurities of piparide intermediate 山东邹平大展新材料有限公司 2022-10-18 CN disclosed
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2021-09-09 US disclosed
EP-3814347-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2021-05-05 EP disclosed
CN-112724078-A Method for removing impurities of piparide intermediate 山东邹平大展新材料有限公司 2021-04-30 CN disclosed
US-8207157-B2 agents result in masking attractive odors from insects that normally would be receptive to the attractants by producing anosmia or hyposmia in the insects; ticks, mites, cockroaches and mosquitoes THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2012-06-26 US disclosed
EP-2170831-B1 Benzazepine derivatives useful as vasopressin antagonists OTSUKA PHARMA CO LTD (JP) 2012-02-15 EP disclosed
EP-2374798-A1 Benzazepine derivatives useful as vasopressin antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-10-12 EP disclosed
EP-2374797-A1 Benzazepine derivatives useful as vasopressin antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-10-12 EP disclosed
US-8003669-B2 Remedy for sleep disturbance MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-23 US disclosed
US-20110071084-A1 BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866430-B2 Naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG USP2 4841/4885SMN1; SMN2 4410/4885MAPK1 450/4885
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG USP2 4841/4885SMN1; SMN2 4410/4885MAPK1 450/4885
US-20110071084-A1 BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS AVPR2, AVPR1B, AVPR1A USP2 2208/4885SMN1; SMN2 4505/4885MAPK1 3034/4885
US-20230089255-A1 COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS DGKA, DGKG, DGKB USP2 3013/4885SMN1; SMN2 4115/4885MAPK1 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.